Schrodinger Inc. (SDGR): Price and Financial Metrics

Schrodinger Inc. (SDGR)

Today's Latest Price: $84.01 USD

9.44 (-10.10%)

Updated Jan 27 6:55pm

Add SDGR to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 78 in Medical - Services

See all "A" rated Strong Buy stocks

SDGR Stock Summary

  • SDGR's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.6 -- higher than just 5.86% of US-listed equities with positive expected earnings growth.
  • SDGR's went public 0.98 years ago, making it older than just 0.14% of listed US stocks we're tracking.
  • SDGR's price/sales ratio is 57.86; that's higher than the P/S ratio of 94.9% of US stocks.
  • Stocks that are quantitatively similar to SDGR, based on their financial statements, market capitalization, and price volatility, are IDN, BLDP, ALTR, INTZ, and LQDT.
  • SDGR's SEC filings can be seen here. And to visit Schrodinger Inc's official web site, go to

SDGR Stock Price Chart Interactive Chart >

Price chart for SDGR

SDGR Price/Volume Stats

Current price $84.01 52-week high $100.75
Prev. close $93.45 52-week low $25.50
Day low $82.81 Volume 1,664,200
Day high $93.00 Avg. volume 765,194
50-day MA $77.08 Dividend yield N/A
200-day MA $66.47 Market Cap 5.84B

Schrodinger Inc. (SDGR) Company Bio

Schrödinger, Inc. provides chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development

SDGR Latest News Stream

Event/Time News Detail
Loading, please wait...

SDGR Latest Social Stream

Loading social stream, please wait...

View Full SDGR Social Stream

Latest SDGR News From Around the Web

Below are the latest news stories about Schrodinger Inc that investors may wish to consider to help them evaluate SDGR as an investment opportunity.

Schrodinger: A Long-Term Compounder With A Literally  Unlimited TAM

In this article I would like to discuss a somewhat underfollowed company with the potential to serve basically every material industry on the planet. Schrodinger (SDGR) at it's core, is a software and computing company. The company formally competes in a market called molecular modelling and if you are confused...

Confounded Interest on Seeking Alpha | January 22, 2021

We're Not Very Worried About Schrödinger's (NASDAQ:SDGR) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | January 15, 2021

Why the success of model portfolios and the paradox of Schrodinger’s cat have a lot in common

Why the success of model portfolios and the paradox of Schrodinger’s cat have a lot in common Submitted 10/12/2020 - 1:48pm By Allan Lane, Algo-Chain – According to a recent article in the Wall Street Journal, the data provider Broadridge Financial Solutions estimates that model portfolios in the US held over USD4 trillion of assets as of September 2020, and to this we can safely add another USD1 trillion if we include the UK. Yet, if you speak to an institutional investor this is an alien world that they do not inhabit. Just pause for a moment on that point, can it really be true that there is a USD5 trillion financial industry that the ‘professionals’ have very little to do with? In short, the answer is yes, and to see why one needs to simply realise that by their very design, model p...

Wealth Adviser | December 10, 2020

Schrödinger Presents Data from Its MALT1 Inhibitor Program at the American Society of Hematology (ASH) 2020 Annual Meeting

Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, presented preclinical data from its wholly-owned MALT1 inhibitor program in B-cell lymphomas at the virtual 62nd American Society of Hematology (ASH) Annual Meeting. MALT1, mucosa-associated lymphoid tissue lymphoma translocation protein 1, is considered a potential therapeutic target for several non-Hodgkin’s B-cell lymphomas as well as chronic lymphocytic leukemia (CLL). Schrödinger scientists have identified novel MALT1 inhibitors that have shown strong anti-tumor activity in preclinical models alone and in combination with ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, and venetoclax, a B-cell lymphoma 2 (BCL-2) inhibitor, two anti-cancer...

Yahoo | December 7, 2020

Schrodinger Inc (SDGR) Q3 2020 Earnings Call Transcript

Thank you, operator, and thank you all for listening in on our third quarter financial results call. Today, you will hear from Ramy Farid, President and Chief Executive Officer; Karen Akinsanya, Chief Biomedical Scientist and Head of Discovery R&D and Joel Lebowitz, our Chief Financial Officer. Before we begin, I'd like to remind you that management will make statements related to our business that are forward-looking, and are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, including without limitation, statements related to the potential advantages of our platform, our strategic plans to accelerate the growth of our software business, and advance our collaborative and internal drug discovery programs, risks related to the COVID-19 ...

Yahoo | November 12, 2020

Read More 'SDGR' Stories Here

SDGR Price Returns

1-mo 5.78%
3-mo 72.22%
6-mo 16.07%
1-year N/A
3-year N/A
5-year N/A
YTD 6.10%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9926 seconds.